Angiogenic Strategy for Human Ischemic Heart Disease

The number of severe ischemic heart disease or idiopathic dilated cardiomyopathy patients who need heart transplant is expected to increase every year. However, the shortage of heart donors is severe, and alternatives to organ transplant are urgently needed. A variety of therapeutic approachs have been attempted, and one of the most promising is regenerative angiogenic therapy. Angiogenic therapy is the stimulation of blood vessel growth in ischemic disease. The therapy for ischemic disease has developed rapidly in the 10 years. I review Angiogenic strategies for ischemic disease include angiogenic protein or gene administration, bone marrow mono nucleous cells implantation, peripheral blood endothelial progenitor cells implantation, and hematogenous cytokine administration. And as conclusions, I think that the use of angiogenic therapy for ischemic heart disease using gene therapy, cell transplantation, and hematogenous cytokine administration will benefit increasing numbers of patients. However, long-term studies monitoring side-effects to establish safety and effectiveness are required. The angiogenic therapy is a promising medical development in the treatment of ischemia that will likely improve the quality of life in patients who have severe ischemic heart disease.